• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 14 – 24/7 Autonomous Journal Article Updating System (AJAUS): Integrated Architecture (AJAUS + OpenClaw + NemoClaw)

Part 14 – 24/7 Autonomous Journal Article Updating System (AJAUS):

Integrated Architecture

(AJAUS + OpenClaw + NemoClaw)

Curator: Aviva Lev-Ari, PhD, RN | Updated March 2026

1. Original AJAUS Concept (from Slide #19)

The Autonomous Journal Article Updating System (AJAUS) was originally designed as a hybrid human + Grok system to enable continuous, traceable updates of LPBI journal articles while maintaining human expert oversight. Its core purpose is to keep our 6,283 journal articles, 48 e-Books, and other trainable assets continuously updated with new scientific findings while maintaining causal reasoning and traceability.

Original AJAUS Concept (Slide #19):

Hybrid Human + Grok Workflow

text
 
HUMAN EXPERT (CEO / Final Approval)
                                   │
                                   ▼
                      AJAUS Orchestration Layer
                                   │
                ┌──────────────────┴──────────────────┐
                │                                     │
           Data Ingestion                     Content Validation
        (New papers, Scoop.it,                 (Ontology check,
         PubMed, Categories)                   Causal Reasoning)
                │                                     │
                └──────────────────┬──────────────────┘
                                   │
                                   ▼
                          Article Update Engine
                        (Grok Causal Reasoning +
                         COM Part 13 SLM-to-LLM)
                                   │
                                   ▼
                          Human-in-the-Loop Review
                                   │
                                   ▼
                       PUBLISHED UPDATED ARTICLE
                (Version History + Traceability)
 
 

2. Original Detailed Workflow (from Appendix #19)

Original AJAUS Detailed Workflow (Pre-NemoClaw):

text
 
HUMAN EXPERT (CEO)
                                   │
                                   ▼
                      AJAUS Core Engine (COM Parts 10–13)
                                   │
                ┌──────────────────┴──────────────────┐
                │                                     │
   Step 1: Data Selection                   Step 2: Validation Models
   (AJAUS Module 1–6)                        (Module 7–12)
   • New papers / Scoop.it                   • Ontology alignment
   • Category matching                       • Causal consistency
   • Expert-selected datasets                • Quality scoring
                │                                     │
                └──────────────────┬──────────────────┘
                                   │
                                   ▼
                          Step 3: Update & Augmentation
                        (Grok Causal Reasoning +
                         SLM-to-LLM Transition – Part 13)
                                   │
                                   ▼
                          Step 4: Human Review & Approval
                                   │
                                   ▼
                       PUBLISHED UPDATED ARTICLE
             (with full traceability and version history)
Caption for Chart in Appendix #19: Original AJAUS hybrid architecture – combining autonomous AI processing with human expert governance for reliable, traceable journal article updates.

3. New Multi-Agent Architecture (AJAUS + NemoClaw Integration)

To evolve AJAUS into a true 24/7 autonomous system, we integrate NVIDIA NemoClaw, an open-source multi-agent orchestration framework. This creates a hierarchical team of specialized AI agents coordinated by a “Chief of Staff” agent.

3.1 High-Level Architecture Diagram: AJAUS + NemoClaw

Foundation for the 2026 multi-agent enhancement with OpenClaw/NemoClaw

 
 
HUMAN EXPERT (CEO)
                                   │
                                   ▼
                      CHIEF OF STAFF AGENT
                 (OpenClaw Orchestrator + Memory Layer)
                                   │
                ┌──────────────────┴──────────────────┐
                │                                     │
           DISCORD CHANNEL                     PERSISTENT MEMORY
       (Real-time Alerts & Notifications)     (Markdown + Learning Log)
                │
                ▼
      ┌───────────────────────────────────────────────────────┐
      │                   AGENT TEAM (OpenClaw)               │
      └───────────────────────────────────────────────────────┘
                │
   ┌────────────┼────────────┬────────────┬────────────┬────────────┐
   │            │            │            │            │            │
Research    Validation    Update      Quality     Deployment   Human-in-
 Agent       Agent       Agent       Agent        Agent       the-Loop
   │            │            │            │            │       Approval
   └────────────┴────────────┴────────────┴────────────┘
                                   │
                                   ▼
                       UPDATED JOURNAL ARTICLE
               (Published + Traceable + Version History)

3.2 New Orchestration Capabilities Inspired by Leading Agentic Systems (March 2026)

Building on the core AJAUS + NemoClaw architecture, we incorporate advanced orchestration principles recently highlighted by Perplexity CEO Aravind Srinivas. The system evolves from instruction-driven to objective-driven orchestration, where the Chief of Staff agent receives a high-level goal and dynamically decomposes, routes, and executes the workflow.

Key New Orchestration Features:

  • Dynamic Multi-Model Routing + Model Council
  • Hybrid Local/Server Execution with Privacy Controls
  • Advanced Context Management for Long-Running Workflows
  • Clear Sub-Agent Specialization and Hand-Off Protocols

These enhancements make AJAUS a true AI Computer for biomedical knowledge management — autonomous, scalable, and clinically reliable.[1]

Footnote [1] Perplexity CEO Aravind Srinivas on agentic orchestration: https://youtu.be/-JBhTBu9ZbA

 

Updated AJAUS + NemoClaw Orchestration Layer

(March 2026 Enhancement)

 

HUMAN EXPERT (CEO)

│

▼

CHIEF OF STAFF AGENT

(Objective-Driven Orchestrator + Memory Layer)

│

┌──────────────────┴──────────────────┐

│                                     │

DISCORD CHANNEL                     PERSISTENT MEMORY

(Real-time Alerts)                       (Dynamic Context Mgmt)

│

▼

┌───────────────────────────────────────────────────────┐

│              AGENT TEAM (NemoClaw / OpenClaw)         │

└───────────────────────────────────────────────────────┘

│

┌────────────┼────────────┬────────────┬────────────┬────────────┐

│            │            │            │            │            │

Research    Validation    Update      Quality     Deployment   Model Council

Agent       Agent       Agent       Agent        Agent      (Dynamic Routing)

│            │            │            │            │

└────────────┴────────────┴────────────┴────────────┘

│

▼

UPDATED JOURNAL ARTICLE

(Published + Traceable + Version History)

Caption: Enhanced orchestration layer incorporating objective-driven routing, multi-model council, hybrid execution, and advanced context management for scalable, autonomous operation.[1]

Footnote [1] Perplexity CEO Aravind Srinivas on agentic orchestration: https://youtu.be/-JBhTBu9ZbA

Our 9 GB corpus, meticulously curated by domain-knowledge experts over 14 years, positions LPBI Group as a premier Healthcare ENGINE for high-quality synthetic data generation. As Mistral CEO Arthur Mensch emphasized, synthetic data is highly efficient for initial model warming-up and compression, but “eventually you do need to have human signal” and “it’s not enough” without it. Our causally structured, high-provenance content — written and validated by PhDs, MDs, and clinical experts — supplies exactly this essential human signal, enabling the generation of superior, clinically accurate synthetic datasets that power reliable agentic AI systems in medicine.

Footnote [2] Mistral CEO Arthur Mensch on synthetic data: https://youtu.be/-JBhTBu9ZbA

4. Key Benefits and Synergy with Existing COM Parts

  • Enables true 24/7 autonomous operation with continuous learning
  • Combines OpenClaw’s agentic orchestration with AJAUS’s domain-specific causal reasoning
  • Directly supports updating all four categories of trainable data assets:
    • Five Primary IP Asset Classes (I, II, III, V, X)
    • Five Additional Domain-aware Data Repositories/Portals
    • 13 Hidden Gems (as ready-made SLMs)
    • 15 Small Language Models (SLMs) from “Articles of Note”
  • Strengthens COM Parts 10–13 and prepares the system for scalable autonomous updates across the entire LPBI ecosystem

5. Human-in-the-Loop Governance (CEO Role)

The human expert remains the CEO with final approval authority, ensuring scientific integrity while allowing agents to handle routine work.

6. Roadmap for Implementation

  • Phase 1: Deploy NemoClaw orchestration layer
  • Phase 2: Configure specialized agents using our 13 Gems
  • Phase 3: Integrate with existing AJAUS workflows
  • Phase 4: Pilot on high-priority domains (Medical Devices 2nd Edition, Respiratory/Infectious Disease)
  • Phase 5: Scale across all trainable data assets

Cross-References: See Slide #19 for the original concept and Appendix #19 for detailed technical specifications. This architecture will power future updates of the Medical Devices Gem (2nd Edition) and all 15 Small Language Models.

NemoClaw Announcement by NVIDIA on March 10, 2026

https://www.cnbc.com/2026/03/10/nvidia-open-source-ai-agent-platform-nemoclaw-wired-agentic-tools-openclaw-clawdbot-moltbot.html?_bhlid=dda085dce502c33fc9545655436a7e148825db2c

 

7. AJAUS Prototype

  • COM – Part 14, AJAUS Prototype Project (Password Protected)

AJAUS Prototype (Flagship of the Tool Factory)

LPBI Group is developing a production prototype of COM Part 14, the flagship 24/7 Autonomous Journal Article Updating System (AJAUS + OpenClaw + NemoClaw). This multi-agent architecture features a Chief of Staff Agent orchestrating specialized Research, Validation, Update, Quality, and Deployment agents, supported by persistent memory and real-time alerting, while maintaining full human-in-the-loop governance.

Phase 1 Pilot (April 2026)

  • 40 carefully selected high-value articles focused primarily on cancer as a disease indication
  • 4-week controlled 24/7 operation
  • Expected outcomes include measurable improvements in update speed, accuracy, discovery of new causal relationships, and significant reduction in human review effort while preserving expert oversight.

Strategic Value The prototype will demonstrate autonomous updating, causal reasoning uplift, and traceability, providing tangible proof of LPBI’s unique data moat for clinical-grade agentic AI in healthcare. It will also serve as the engine for future 2nd Editions of the BioMed e-Series, refreshment of the 13 Hidden Gems, and enhancement of the 15 “Articles of Note” collections for Small Language Models.

UPDATE on 5/10/2026

Understanding the Agentic AI Hierarchy: From LLM to Full Agentic Systems

Explanation Text:

The Agentic AI Hierarchy (as defined by leading AI practitioners)

Level

Term

Core Capability

Limitation / Advancement

1

LLM

Reads, writes, explains, answers

No real-time data, can hallucinate, forgets context

2

RAG

Retrieves external data and grounds responses

Adds accuracy and reduces hallucination

3

AI Agent

Thinks + acts using tools, APIs, code

Executes tasks autonomously with short- and long-term memory

4

Agentic AI

Multiple agents collaborating as a team

Plans, coordinates, shares memory, pursues long-term goals

SOURCE 

https://www.linkedin.com/posts/aiforexecutives-official_llm-vs-rag-vs-ai-agent-vs-agentic-ai-%F0%9D%97%95%F0%9D%97%B2%F0%9D%97%B0%F0%9D%97%BC%F0%9D%97%BA%F0%9D%97%B2-activity-7440441956507336704-FBqI/

Why This Matters for AJAUS (COM Part 14)

AJAUS is deliberately designed as a Level 4 Agentic AI system — not a single LLM or simple agent, but a governed, multi-agent orchestration layer that:

  • Operates with human-in-the-loop oversight
  • Uses LPBI’s 9 GB high-provenance multimodal corpus as its trusted foundation
  • Connects to the Rosetta Stone Ontology (COM Part 15) for causal, clinically accurate reasoning and translational mapping
  • Ensures every action is traceable, auditable, and compliant

Cross-reference to COM Part 15: The Rosetta Stone Ontology provides the semantic and causal intelligence layer that turns raw agentic execution (AJAUS) into clinically trustworthy, high-provenance reasoning — the critical bridge between agent actions and real biomedical meaning.

Key Takeaway for LPBI We are not building another LLM or basic agent. We are building the trusted Agentic AI orchestration platform that the entire industry will need.

Market Validation: Emergence of Production-Grade Managed Agent Infrastructure

Anthropic has launched Claude Managed Agents (April 8, 2026) — a full production infrastructure that provides an agent harness + managed backend (sandboxing, session management, tool orchestration, guardrails, and scaling).

This allows teams to move from prototype agents to enterprise deployment in days instead of months. Early customers include Notion, Asana, Rakuten, Sentry, and Vibecode.

This announcement validates the strategic direction of AJAUS as a governed, production-ready agentic orchestration layer. While Anthropic provides the managed infrastructure, AJAUS supplies the domain-specific, high-provenance biomedical intelligence (LPBI’s 9 GB corpus + Rosetta Stone Ontology from COM Part 15) and human-in-the-loop governance required for safe, clinically trustworthy deployment in regulated health AI environments.

Status Design and planning complete. Pilot launch targeted for April 2026.

  • COM – Part 14, AJAUS Prototype Project (Password Protected)

 

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

This page has the following sub pages.

  • COM – Part 14, AJAUS Prototype Project (Password Protected)

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI in Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
    • A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters by KOL (March 1 – June 10, 2026, to be extended to Present) June 11, 2026
    • In Memoriam: Professor Yitzhak Apeloig, President and Distinguised Professor of the Technion June 4, 2026
    • Top VC Investors in AI / Health AI in 2026 May 26, 2026
    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...

    %d